Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Condition(s):Colorectal Cancer Stage IV; No Evidence of Disease StateLast Updated:May 17, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Colorectal Cancer Stage IV; No Evidence of Disease StateLast Updated:May 17, 2023Recruiting
Condition(s):Metastatic Colorectal Cancer; No Evidence of Disease Status; ctDNA MonitoringLast Updated:December 2, 2022Recruiting
Condition(s):Squamous Cell CarcinomaLast Updated:February 21, 2024Recruiting
Condition(s):Metastatic Colorectal Cancer,NEDLast Updated:December 12, 2023Recruiting
Condition(s):Multiple SclerosisLast Updated:March 21, 2024Recruiting
Condition(s):Colorectal Cancer ScreeningLast Updated:January 12, 2023Recruiting
Condition(s):Colorectal Cancer MetastaticLast Updated:August 31, 2023Recruiting
Condition(s):Breast Cancer, Early Breast CancerLast Updated:February 29, 2024Recruiting
Condition(s):Multiple SclerosisLast Updated:March 7, 2024Recruiting
Condition(s):Relapsing-Remitting Multiple SclerosisLast Updated:February 2, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.